Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to establish if consolidation of imatinib-treated patients in stable
DMR through the addition of asciminib, can lead to superior rates of TFR1, compared to
imatinib alone in Chronic Phase-Chronic Myelogenous Leukemia patients.